Search the Newsreel

AAON (AAON) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Monday, Aug. 10, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Director of Investor Relations-Joseph Mondillo President and Chief Executive Officer-Matthew Tobolski Chief Financial Officer-Andy Cheung Full Conference Call Transcript Operator: Thank you for standing by. At this time, …

Is Fair Isaac (FICO) Undervalued On New Mortgage And Fraud Platform Deals?

Fair Isaac (FICO) has seen renewed attention due to new partnerships expanding its credit scoring and fraud decisioning capabilities for lenders. Despite a recent stock price fall, the company is considered 28.2% undervalued, with a fair value pegged at $1,512.25. The transition to SaaS …

Class action filed against Aardvark Therapeutics over safety issues and FDA clinical hold on drug trial.

A class action lawsuit has been filed against Aardvark Therapeutics by investors claiming the company misled them about the safety and prospects of its drug ARD-101. This follows a significant stock drop after Aardvark paused a Phase 3 clinical trial and the FDA issued …

Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders to Contact the Firm for Information About Their Rights

The Rosen Law Firm has announced a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) on behalf of investors who purchased securities between February 13, 2025, and May 14, 2026. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the …

AARD INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Aardvark Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

A class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) alleging that the company made false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased Aardvark shares between February 13, 2025, and May 14, 2026, …

STAAR Surgical (NASDAQ:STAA) Shares Down 6.6% Following Analyst Downgrade

STAAR Surgical (NASDAQ:STAA) shares dropped 6.6% after Stifel Nicolaus lowered its price target from $31 to $28 while maintaining a hold rating. The company's stock now has a consensus "Hold" rating and an average price target of $28.40 from analysts. Despite exceeding revenue expectations …

Canaan mined 46 bitcoins in July, boosting its crypto treasury and authorizing share buybacks using digital assets.

In July 2026, Canaan Inc. mined 46 bitcoins, increasing its total cryptocurrency holdings to 1,917 BTC and 3,952 ETH, while also recovering from wildfire disruptions. The company has authorized the use of its crypto treasury for share repurchases to enhance shareholder value due to …

Deciphering Staar Surgical (STAA) International Revenue Trends

Aarti Pharmalabs sets Sept 15 record date for ₹2 final dividend

Canaan (Nasdaq: CAN) mines 46 BTC, faces 2027 bid deadline

Canaan Inc. reported mining 46 BTC in July 2026, bringing its digital asset treasury to 1,917 BTC and 3,952 ETH. The company has transferred its ADS listing to the Nasdaq Capital Market and has until January 11, 2027, to regain compliance with Nasdaq's minimum …

A wildfire disrupted Canaan's Alborz joint venture—what happened next?

Canaan Inc. (NASDAQ: CAN) released its July 2026 Bitcoin mining update, reporting 46 BTC mined and a digital asset treasury of 1,917 BTC and 3,952 ETH. The company highlighted the stabilization of its Alborz joint venture operations after a wildfire disruption and noted its …

Ottobock hebt Prognose an: Starkes Quartal treibt Gewinn und Aktie

Regaal Resources Q1 Results: Earnings call audio uploaded for investors

Aarey Drugs Q1 Results: Revenue up 145% YoY, net profit falls 60%

Regaal Resources Q1 Profit Jumps 47% to ₹13.3 Cr

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit

The Rosen Law Firm has announced a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) on behalf of investors who purchased securities between February 13, 2025, and May 14, 2026. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the …

Aarvi Encon Share Price Target 2027 to 2030: Analyst Outlook

Aarti Pharmalabs Share Price Target 2027 to 2030: Analyst Outlook

Regaal Resources net profit rises 47% YoY to ₹133.28 million in Q1FY27

Xaar PLC (FRA:XAR) (H1 2026) Earnings Call Highlights: Revenue Growth and Strategic Pivots ... By GuruFocus

Aarvi Encon approves ₹2 dividend, FY26 financials at 38th AGM

Aartech Solonic Q1 FY27 Results: Revenue Up 68%, PAT Rs 1 Crore

Aarvi Encon revenue up 27% in FY26 to ₹649.85 crore; declares ₹2 dividend

Albaad Massuot Yitzhak Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Is STAAR Surgical (STAA) Still Below Fair Value After Its Return To Profit?

Analysts Expect Maanshan Iron & Steel Company Limited (HKG:323) To Breakeven Soon

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts

Why STAAR Surgical (STAA) Is Up 8.1% After Returning To Profit Under New CEO Warren Foust – And What's Next

STAAR Surgical (STAA) reported a significant return to profitability in Q2 2026 with sales of US$93.54 million and net income of US$8.06 million, reversing previous losses. This turnaround coincides with Warren Foust's appointment as CEO, leading to a positive market reaction with the stock …

Growth Investors: Industry Analysts Just Upgraded Their AAON, Inc. (NASDAQ:AAON) Revenue Forecasts By 11%

Analysts have significantly upgraded AAON, Inc.'s revenue forecasts for 2026 by 11% to US$2.3 billion, representing a 19% improvement over the last year. Earnings per share are also expected to rise by 25% to US$2.42. Despite these positive revisions, the consensus price target has …

Consolidated Grunenfelder Saady Holding Company Reports Earnings Results for the First Quarter Ended June 30, 2026

Why STAAR Surgical (STAA) Is Up 8.1% After Q2 Profit Rebound And New CEO Appointment

Ströer SE & Co. KGaA (ETR:SAX) hat soeben seine Ergebnisse für das zweite Quartal veröffentlicht und Analysten aktualisieren ihre Schätzungen

STAAR Surgical (STAA) Gives Warren Foust The CEO Role After Its Profit Reset

STAAR Surgical has appointed Warren Foust as its permanent President and CEO, following a period of operational reset and a return to profitable growth under his interim leadership. Foust's promotion from COO and interim co-CEO signifies a defined leadership direction for the ophthalmic device …

STAAR Surgical (STAA) Stock May Be 13% Below Fair Value Following Q2 Earnings Preview

We Think Aardvark Therapeutics (NASDAQ:AARD) Needs To Drive Business Growth Carefully

Analysten passen ihre Prognosen für die Ottobock SE & Co. KGaA (ETR:OBCK) nach der Veröffentlichung der Halbjahresergebnisse an